Showing 4871-4880 of 5570 results for "".
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal wi
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Tempted by Temptu to Debut at AAD Annual Meetinghttps://practicaldermatology.com/news/tempted-by-temptu-to-debut-at-aad-annual-meeting/2458691/At the upcoming 2016 AAD annual meeting, TEMPTU introduces its groundbreaking TEMPTU Air, the first handheld airbrush makeup device for skin perfection. Using the company’s patented Airpod and Atomized AirFlow™ Technology, TEMPTU Air delivers a micro-fine mist that floa
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Endo International Launches New Phase 2b Study of CCH for Cellulitehttps://practicaldermatology.com/news/endo-international-launches-new-phase-2b-study-of-cch-for-cellulite/2458699/A Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of as cellulite is about to get started, Endo International plc reports. CCH is intended to target and lyse collagen tethers with the goal of releasing the skin di
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Novel Jasmonate Compound Takes On Fine Wrinkles, Poreshttps://practicaldermatology.com/news/novel-jasmonate-compound-takes-on-fine-wrinkles-pores/2458704/The active ingredient in Lancome’s Visionnaire family of products safely and effectively helps improve the appearance of fine wrinkles, skin tone and pores
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i